- Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancerWang, Zhen; Wei, Lingyun; Li, Jing; Zhou, Han; Li, Si; Chen, Dongsheng; Yu, Yangyang; Zhao, Lele; Zhu, Xixu*; Song, Yong*Translational Lung Cancer Research, 2021, 10(12): 4368-+.被引 14
- Analysis of Circulating Tumor DNA Kinetics during Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung CancerChen E. L.; Chaudhuri A. A.; Nabet B. Y.; Chabon J. J.; Merriott D. J.; Loo B. W. Jr.; Alizadeh A. A.; Diehn M.60th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), 2018-10-21 To 2018-10-24.
- Pembrolizumab vs chemotherapy in Chinese patients with PD-L1-positive NSCLC: 4-year update from KEYNOTE-042 China studyWu, Yi-Long; Fan, Yun; Zhou, JianYing; Zhang, Li; Zhou, Qing; Li, Wei; Hu, ChengPing; Chen, GongYan; Zhang, Xin; Zhou, CaiCun; Gonzalez Arenas, Carmen; Fu, Wei; Wu, Helen; Mok, TonyAnnual Meeting of the American-Association-for-Cancer-Research (AACR), New Orleans, LA, 2022-04-08 To 2022-04-13.被引 1
期刊论文
combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer (vol 10, pg 4368, 2021)
7阅读
